Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (2475)	10/25/1997 8:58:00 AM
From: Gary L. Kepler	Respond to of 6136

Source for short interest. Since many have questions. viwes.com

To: JOHN W. who wrote (2475)	10/25/1997 7:22:00 PM
From: Steve Fancy	Respond to of 6136

>>...It all sounds great--if you bought the stock a year ago. It's up 126% since then. But today, with a fiscal 1998 P/E hovering around 75...<< I don't know how Fortune magazine figures their P/E, must have been before the earnings revisions. In checking Zacks and First Call, I found the following mean estimates, P/E's calculated with stock price of 50: Zacks First Call 98 EPS/PE .87/57.47 .89/56.17 99 EPS/PE 1.86/26.88 1.75/28.57 Next 5 year growth rate 67.5 N/A For the heck of it, PaineWebber's revised estimates as of 10/15: 98 EPS/PE 1.00/50.00 99 EPS/PE 2.31/21.64 sf